Hematology and/or Oncology

USING REAL-WORLD PATIENT SCENARIOS AND SIMULATIONS TO OVERCOME BARRIERS TO APPROPRIATE USE OF ORAL ANTICOAGULANTS-PROVOKED VTE
Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), is a common and serious medical condition associated with significant morbidity, mortality, and cost.
CME: 0.5
Integrating Multidisciplinary Care in the Diagnostic and Therapeutic Management of B-cell Non-Hodgkin Lymphomas
This webcast will examine the implications of B-cell NHLs as a disease, including accurate diagnosis, risk stratification and molecular biomarkers, to aid prognosis and treatment choice.
CME: 1.0
2018 Webinar: Controversies in Neoadjuvant Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer
Identify benefits of neoadjuvant therapy in patients with borderline resectable pancreatic cancer
CME: 1.0
Enhancing Supportive Care for Pediatric Patients with High-Risk Neuroblastoma: A Focus on Nursing Practice Strategies
This activity is intended for oncology specialists who treat pediatric patients with high-risk neuroblastoma, such as physicians, physician assistants and social workers.
CME: 1.0
PARP in Practice: Expanding Options in the Maintenance Setting for Ovarian Cancer
Formulate management plans and review emerging strategies for adverse events associated with PARP inhibitors in the frontline, maintenance setting.
CME: 1.0
Analysis of Recently Published Acute Lymphoblastic Leukemia Articles / Studies
Summarize the latest research developments in the treatment of acute lymphoblastic leukemia
CME: 1.25
Follicular Lymphoma: Best Practices in the Therapeutic Management
Assess optimal time to initiate treatment for FL in order to delay disease progression and maintain patient quality of life
CME: 1.0
Should a Patient with a 2 cm HER2+/TNBC Clinically Node Negative Receive Neoadjuvant Therapy?
Should a Patient with a 2 cm HER2+/TNBC Clinically Node Negative Receive Neoadjuvant Therapy? This webinar will present data and compare and contrast the benefits and limitations of upfront surgery and neoadjuvant therapy for resectable HER2+/TNBC
CME: 1.0
CDK 4/6 INHIBITION IN BREAST CANCER: SELF-STUDY MODULE II
This CME and CE activity will evaluate proper dosing administration, monitoring, and adherence strategies of CDK 4/6 inhibitors for the treatment of estrogen receptor–positive, HER2-negative advanced breast cancer.
CME: 1.0

Hematology/Oncology